BioCentury
ARTICLE | Clinical News

TD-6450: Phase IIa started

July 18, 2016 7:00 AM UTC

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir ( BI 201335) with and without ribavirin for 12 weeks in 25 patients. Tre...